METHOD AND SYSTEM FOR THE ADMINISTRATION OF A PULMONARY SURFACTANT BY ATOMIZATION

Fig. 1

Abstract: The method and system according to preferred embodiments of the present invention allows optimizing the dispensing of aerosol medicaments. In particular, the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention, the delivery of the atomized medicament is done by means of an air blasting technique.
METHOD AND SYSTEM FOR THE ADMINISTRATION OF A PULMONARY SURFACTANT BY ATOMIZATION

Description

Field of technology

The present invention relates to the field of retropharyngeal instillation of medicament and particularly to a method and system for the administration of a pulmonary surfactant by atomization.

Background of the invention

Administration of medicament in the lungs is often faced with the problem of finding the right balance between the efficacy and the invasiveness of the treatment. This is particularly difficult with infants (hereinafter the term neonates is used as synonymous of infants.). Preterm neonates may be affected by nRDS (neonatal Respiratory Distress Syndrome), a lung disease due to generalized immaturity which causes the lack of pulmonary surfactant. For many years, nRDS has been treated by administration of exogenous pulmonary surfactants as bolus through endotracheal instillation to the intubated pre-term neonates kept under mechanical ventilation. Although this treatment is very effective, as proven by the reduced mortality, it may present some drawbacks which are intrinsic to the
mechanical ventilation (volu/barotrauma) and to the intubation procedure which is anyway invasive.

In view of the potential complications associated with intubation and mechanical ventilation, attention has been focused on different approaches of administration of exogenous pulmonary surfactants.

In particular, as a possible respiratory support, use of non-invasive ventilation procedures such as early nasal Continuous Positive Airway Pressure (nCPAP), that delivers air into the lungs through specifically designed nasal devices such as masks, prongs or tubes, has been introduced in neonatal intensive care.

Following this orientation, in the last fifteen years great attention has also been paid to finding an alternative way for pulmonary surfactant administration. Most of the performed studies have been focused on the administration of nebulized surfactant (i.e. particles with a mass diameter <10µm) by means of commercial nebulizers connected to the ventilator circuit, based on the hypothesis that a gentler and more gradual administration should prevent the high cerebral blood fluctuation that may occur with bolus administration (See e.g. Mazela J, Merrit TA, Finner NN "Aerosolized surfactants" Curr Opin Pediatr. 2007; 19(2): 155; or Mazela J, Polin RA "Aerosol delivery to ventilated newborn infants: Historical challenges and new directions" Eur J Pediatr. 2011:1-12; or Shah S "Exogenous surfactant: Intubated present, nebulized future?" World Journal of Pediatrics. 2011; 7(1): 11-5). Albeit the surfactant results more homogenously distributed, the improvements in the lung functionalities obtained in the different studies are very
contrasting and they don’t evidence the effectiveness of the nebulization approach. In other studies surfactant nebulization system was connected to non-invasive ventilator settings (i.e. CPAP through nasal prongs); in these conditions the amount of nebulized surfactant that reached the lung appeared to be negligible (less than 20%). Moreover nebulized surfactant administered during CPAP has no conclusive beneficial impacts on lung functionality as shown in pilot studies on preterm neonates (see e.g. Berggren E, Liljedhal M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al "Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome" Acta Paediatrica 2000;89 (4): 460-4; or Finner NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R "An open label, pilot study of Aerosurf combined with nCPAP to prevent RDS in preterm neonates" Journal of aerosol medicine and pulmonary drug delivery. 2010; 23(5): 303-9; or Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, et al "Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants" Pediatr Pulmonol. 1997; 24(3):222-4). The studies are very variegated and the authors apply different conditions with reference to several parameters, e.g.: 1) placement and type of aerosol generator, 2) mode of ventilation, 3)humidity, 4) air flow, 5) particle size, 6) nRDS models, 7) surfactant dilution, etc.

Therefore it is difficult making a proper comparison among them. However known systems do not generally prove to be very effective.
Moreover, when an aerosolized surfactant is administered with a nebulizer through a mask and not synchronized with the neonate’ breath, some part can be exhaled during expiration and either deposits into the upper airways or tubing/connections or it is exhaled by the expiratory limbs. Moreover, the delivery of nebulised surfactant adds dead-space to the breathing circuits and, considering that preterm newborns may have a tidal volume of 1ml or even less, this can promotes CO2 retention that, eventually, could become dangerous if a final situation of hypercapnia is achieved.

An interesting approach that could partially mitigate the above risk has been proposed by Wagner et al (Wagner MH, Amthauer H, Sonntag J, Drenk F, Eichstadt HW, Obladen M "Endotracheal surfactant atomization: an alternative to bolus instillation?" Crit Care Med. 2000; 28(7):2540) showing encouraging results. It is based on a modified tracheal tube with an atomizer inserted at the tip of the tube which produces particles, that have a SMD (Souter Mean Diameter) >100 µm, only during inspiration (identified by an operator). The choice of putting the atomizer directly into the tube has been technologically challenging.

The promising results of the Wagner approach are probably due to the bigger dimensions of the particles which allow the distribution and absorption of the pulmonary surfactant similar to the mechanisms involved in the bolus administration. In particular, it can be hypothesized that big particles will deposit on more central airways, being able to reach the non-expanded alveoli by diffusion gradient, Marangoni effect and capillarity, while, on the contrary, the small
nebulized particles, which are able to pass through the upper airways, are likely to be either exhaled during expiration or being deposited into the already opened alveoli which produces the airflow during breathing, without reaching the atelectatic region of the lung and contributing to an even more inhomogeneous distribution of lung time constants. Another advantage of Wagner is that the pulmonary surfactant is administered during inspiration phase only and this helps in better controlling the quantity of medicament effectively delivered (with improvements in terms of saving and clinical results).

A drawback of Wagner is that the tube must reach the trachea (where the nebulizer is placed), in order to be able to deliver the big sized particles which would be filtered out by the upper airways, and this procedure is invasive and can cause problems, in particular for neonates. On the other hand, all known prior art systems implementing a non-invasive (i.e. not entering the tracheal tube) delivery method are capable of administering only small sized particles which are able to overcome the outer barrier, but are less efficient in reaching all the lung regions needing treatment.

Furthermore, according to Wagner experiment, the "synchronization" of the delivery of medicament with the inspiration rhythm is done manually, which is not ideal for obvious reasons including a waste of the product. On the other hand all attempts known in the art for implementing such synchronization, for example those described in EP 692273, are depending on the presence of devices such as a
mechanical ventilator. However, this solution needs connections to the airway of the newborn, adding dead space and mechanical load to the patient's breathing.

For all these reasons, an improved non-invasive method and system for administering the exogenous surfactant which is capable of combining the advantages of big size particle nebulization with proper automatic synchronization of the delivery would be greatly appreciated.

**Objects of the invention**

It is an object of the present invention to overcome at least some of the problems associated with the prior art.

**Summary of the invention**

The present invention provides a method and system as set out in the accompanying claims.

According to one aspect of the present invention, we provide a system for delivering a medicament to spontaneously breathing patients, comprising: i) a flexible catheter adapted to reach the retro-pharyngeal region of the patient, the catheter including at least a first channel being adapted to convey in the patient's pharyngeal region a flow of liquid medicament and at least a second channel
adapted to convey in the patient’s pharyngeal region a pressurized flow of gas; ii) first pump means connected to a first end of the at least first channel, adapted to create a pressure which pushes the column of liquid medicament towards the second end of the at least first channel; iii) second pump means connected to a first end of the at least second channel, adapted to create the flow of pressurized gas; so that when the column of liquid medicament and the pressurized gas meet in the pharyngeal cavity, the liquid column is broken into a plurality of particles causing the atomized medicament to be delivered into the patient's lungs; iv) a pressure sensor connected to the at least first channel for measuring a value indicative of the pressure in the patient pharyngeal cavity, such value being use to determine whether the patient is in an inspiration or in an expiration phase and wherein the first pump means are selectively activated only during inspiration phase.

The use of the liquid-filled lumen of the catheter for estimating the pressure swings at the pharyngeal cavity allows specific advantages compared to other approaches: 1) it provides a very fast response of the catheter-pressure transducer system (liquids are not compressible and adds a minimal compliance of the measuring system, resulting in very fast time constants), allowing a fast detection of the newborns breathing phase (respiratory rate in small preterm neonates can be greater than 60 breaths per minute, one order of magnitude greater than for adults); 2) the use of small and low-cost disposable catheters with no extra lumens for pressure sampling and with the pressure transducer being placed close to the main
device; 3) the presence of liquid in the lumen prevents the tip of the catheter to be occluded by the fluids always present in the pharynx, for example saliva or moist due to the water vapor saturated environment, an important advantage against air-filled lumens for pressure sensing; 4) as the pressure swing due to the low-resistance pathway provided by the liquid-filled lumen is small compared to the gas ones, it is much easier to detect the very small pressure swings in the pharyngeal cavity due to breathing of the neonate, which are in the order of lcmH$_2$O.

Preferably the catheter is made of flexible plastic material and as an alternative it can include partially rigid scaffolding. Preferably the at least second channel includes a plurality of channel arranged around the first channel.

Preferably, the aerosol medicament comprises an exogenous pulmonary surfactant, e.g. selected from the group consisting of modified natural pulmonary surfactants (e.g. poractant alfa), artificial surfactants, and reconstituted surfactants, while the pressurized gas includes air or oxygen.

According to a further embodiment the catheter includes spacers means arranged on its external surface so that, when the catheter is in place for the aerosol treatment, the second end of the at least first and at least second channel are kept separated from the wall of the pharyngeal cavity.
In a second aspect of the invention, we provide a method for preventing and/or treating a respiratory distress syndrome in spontaneously breathing patients, said method comprising the step of delivering an atomized medicament to the retro-pharyngeal region of the patient by means of a multi-channel flexible catheter a low pressure column of liquid medicament through at least a first channel of the multi-channel catheter and an pressurized flow of gas through at least a second channel of the multi-channel catheter; wherein the liquid column of medicament is broken into a plurality of particles when the liquid column and the pressurized flow of gas meet in the retro-pharyngeal cavity. Preferably the method comprises the step of detecting the inspiration activity of the patient, preferably by means of a pressure sensor being connected to the at least first channel; wherein the step of providing is performed only during the inspiration activity.

More preferably, the method of the invention comprises applying to the patient a non-invasive ventilation procedure such as nasal Continuous Positive Airway Pressure (nCPAP).

In a third aspect of the invention, we provide a kit comprising: a) a pharmaceutical composition comprising a pulmonary surfactant suspended in a pharmaceutically acceptable aqueous medium; b) the system of the invention; c) means for positioning and/or facilitating the introduction of the catheter into the retro-pharyngeal region; and d) container means for containing the pharmaceutical composition, the system and the positioning means. In a fourth aspect of the
invention, we provide a method for preventing and/or treating a respiratory distress syndrome in spontaneously breathing pre-term neonates, said method comprising the step of delivering a pulmonary surfactant in the retro-pharyngeal cavity of said neonates. A still further aspect of the present invention provides a computer program for controlling the above described method.

The method and system according to preferred embodiments of the present invention allows optimizing the dispensing of surfactant with an efficient delivery of the atomized particles to the lungs without requiring an invasive operation for placing the catheter. The method and system of the present invention provides several advantages including: a more gentle atomizing process, thanks to the air-blasting atomizing catheter, whose mechanical impact on the surfactant is minimal; an easier manufacturing and a more compact design of the atomizing catheter thanks to the absence of the ending taper; the possibility to monitor and to synchronize to the breathing pattern of the patient without the introduction of a sensor, connections at the airway opening or a second lumen; the flexibility of the device, which can be used either during spontaneous breathing or when non-invasive respiratory support is provided, such as during nCPAP or other non-invasive ventilation procedures such as nasal intermittent positive-pressure ventilation (NIPPV); the use of components which are already familiar to the hospital personnel, e.g. catheters and disposable pressure sensors (similar to the ones used for invasive monitoring of blood pressures); all the part in contact with the pulmonary surfactant and the patient are low cost and disposable, granting for
hygienically and safer treatments than those of the prior art, which is particularly important when the patient is a pre-term neonate.

**Brief description of the drawings**

Reference will now be made, by way of example, to the accompanying drawings, in which:

Figure 1 is a schematic diagram of the system implementing a preferred embodiment of the present invention;

Figure 2 shows an example of multi channel catheter according to an embodiment of the present invention;

Figure 3 shows as example the particles dimension of surfactant (Curosurf™) atomized according to the preferred embodiment of the present invention.

Figure 4a and 4b represent respectively a pressure sensor according to an embodiment of the present invention and the circuit controlling the pressure sensor;

Figure 5 shows an exemplificative retropharyngeal pressure signal acquired on a preterm neonate.

Figure 6 shows the steps of the method according to a preferred embodiment of the present invention;
Figure 7 shows a diagram of tidal volume related to fetuses being treated with the
method and system according to an embodiment of the present invention;

Definitions

With the term "pulmonary surfactant" it is meant an exogenous pulmonary surfactant administered to the lungs that could belong to one of the following classes:

i) "modified natural" pulmonary surfactants which are lipid extracts of minced mammalian lung or lung lavage. These preparations have variable amounts of SP-B and SP-C proteins and, depending on the method of extraction, may contain non-pulmonary surfactant lipids, proteins or other components. Some of the modified natural pulmonary surfactants present on the market, like Survanta™ are spiked with synthetic components such as tripalmitin, dipalmitoylphosphatidylcholine and palmitic acid.

ii) "artificial" pulmonary surfactants which are simply mixtures of synthetic compounds, primarily phospholipids and other lipids that are formulated to mimic the lipid composition and behavior of natural pulmonary surfactant. They are devoid of pulmonary surfactant proteins;

iii) "reconstituted" pulmonary surfactants which are artificial pulmonary surfactants to which have been added pulmonary surfactant proteins/peptides isolated from animals or proteins/peptides manufactured through recombinant technology such as those described in WO 95/32992 or synthetic pulmonary
surfactant protein analogues such as those described in WO 89/06657, WO 92/22315 and WO 00/47623.
The term "non-invasive ventilation (NIV) procedure defines a ventilation modality that supports breathing without the need for intubation.

**Detailed description of preferred embodiments**

With reference to Figure 1 an implementation of the method and system according to a preferred embodiment of the present invention is illustrated. In the example here discussed we address the problem of delivering the right amount of atomized medicament to a patient: in particular we administrate a pulmonary surfactant (e.g. poractant alfa, commercially available as Curosurf™ from Chiesi Farmaceutici SpA) to e.g. a preterm neonate.

However, any pulmonary surfactant currently in use, or hereafter developed for use in respiratory distress system and other pulmonary conditions could be suitable for use in the present invention. These include modified natural, artificial and reconstituted pulmonary surfactants (PS).

Current modified natural pulmonary surfactants include, but are not limited to, bovine lipid pulmonary surfactant (BLESTM, BLES Biochemicals, Inc. London, Ont), calfactant (Infasurf™, Forest Pharmaceuticals, St. Louis, Mo.), bovactant (Alveofact™, Thomae, Germany), bovine pulmonary surfactant (Pulmonary
Examples of artificial surfactants include, but are not limited to, pumactant (Alec™, Britannia Pharmaceuticals, UK), and colfosceril palmitate (Exosurf™, GlaxoSmithKline, Middlesex).

Examples of reconstituted surfactants include, but are not limited to, lucinactant (Surfaxin™, Discovery Laboratories, Inc., Warrington, Pa.) and the product having the composition disclosed in Table 2 of Example 2 of WO 2010/139442, whose teaching is incorporated herein by reference.

Preferably, the pulmonary surfactant is a modified natural surfactant or a reconstituted surfactant. More preferably the pulmonary surfactant is poractant alfa (Curosurf™).

The dose of the pulmonary surfactant to be administered varies with the size and age of the patient, as well as with the severity of the patient's condition. Those of skill in the relevant art will be readily able to determine these factors and to adjust the dosage accordingly.

A catheter 101 conveys atomized medicament (e.g. surfactant) directly to the retro-pharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonate suffering from neonatal Respiratory
Distress Syndrome (nRDS). According to a preferred embodiment of the present invention the catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. In a preferred embodiment of the present invention the delivery of the atomized medicament is done by means of an air blasting technique. Using air to assist atomization is a well known technique that grants a fully developed atomization also when low pressure and low flow conditions are required (see e.g. Arthur Lefebvre, "Atomization and spray", Taylor and Francis, 1989). Such technique is based on a relatively small amount of gas (e.g. air, but it could be other compressed gas, e.g. oxygen, nitrogen, or helium) which flows in one or more separate channels than the medicament which is delivered in a liquid form; the air flow accelerates and breaks the liquid column, inducing the atomization of the medicament. Therefore the catheter 101 includes a plurality of channels (at least two, one for the medicament and one for the air) for conveying contemporarily the medicament and the air flow. The liquid medicament column is broken up in droplets by the turbulence due to the air flowing next or around when the two flows (air and liquid medicament) exit the catheter channels and meet in the retro-pharyngeal region. The atomized droplets have a mean diameter of at least 80 micron, preferably higher than 100 micron, more preferably of 80-150 micron. It is believed that this effect is caused by the air flow which accelerates the fluid sheet instability. The air also helps in dispersing the droplets, preventing
collision among them and facilitating the diffusion of the medicament in the lungs by reducing the likelihood of contact between the particles and the wall of the retropharyngeal cavity.

In a preferred embodiment of the present invention the medicament (e.g. the surfactant) is supplied by means of a pump 103 connected to one end of the catheter, which forces the liquid medicament out of the opposite end of the catheter where it meets the air flow (conveyed by a different channel of the catheter) and is atomized, i.e. broken into a plurality of small particles (droplets) by the pressurized air. Pump 103 may be realized by a device able to generate a flow, such as an infusion pump: in a preferred embodiment of the present invention the pump 103 is made of a mechanical frame comprising a structure that holds a syringe containing the liquid medicament and a stepper motor that pushes the syringe piston. In an embodiment of the present invention, pump 103 can be controlled by a control unit 109; such control unit can be embodied in a computer, a microprocessor or, more generally any device capable of data processing activity. A pump device 105 (possibly including a pressurized source and pressure regulator and filter) is connected to the one or more channel conveying the air flow. Those skilled in the art will appreciate that with the term pump we include any device capable of providing a pressure to either a liquid flow or a flow of gas. Pump 105 can be controlled by a control unit, as described for the pump 103. The flow of the pump 103 should be in the range of 9-18 ml/H while the pressure of
the pump 105 should be comprised between 0.4 and 0.8 Atm (\(1 \text{ Atm} = 1.01325 \text{ Bar}\)).

In a preferred embodiment of the present disclosure the catheter 101 includes multiple channels, with a main (e.g. central) channel conveying the surfactant, being surrounded by a plurality of additional channels (e.g. lateral) which convey a pressurized air flow). The air blasting technique here described provides the advantage of a more gentle fragmentation of the surfactant. Current atomizers for drug delivery are normally based on plain orifices, while the method according to the present disclosure employs an atomizing catheter using the air blasting approach. The geometrical configuration of the plain orifice normally presents a narrowing at the tip of the catheter, the nozzle, which accelerates the liquid producing an high instability in presence of an high pressure drop (more than 1 Atm) and, as a consequence, the fragmentation of the liquid in particles. On the contrary, the air blasting catheter according to a preferred embodiment of the present disclosure is a multi-lumen catheter: the surfactant flows into the main lumen while pressurized air flows in the lateral ones. The turbulences generated by the small airflow fragment the surfactant in a very 'gentle' way. Moreover, the use of plain orifices would require very high differential pressure across the nozzle to induce atomization, while the air blasting atomizer doesn't need high driving pressure to the surfactant, as the atomizing process is driven by the turbulence of the air around the surfactant.
The pulmonary surfactant is preferably administered as a suspension in a sterile pharmaceutically acceptable aqueous medium, preferably in a buffered physiological saline (0.9% w/v sodium chloride) aqueous solution. Its concentration shall be properly adjusted by the skilled person in the art.

Advantageously, the concentration of the surfactant might be comprised between 2 and 160 mg/ml, preferably between 10 and 100 mg/ml, more preferably between 40 and 80 mg/ml.

The applied volume should generally be not more than 5.0 ml, preferably not more than 3.0 ml. In some embodiments, it could be 1.5 ml or 3 ml.

A possible additional feature of the method and system according to the present disclosure is that of synchronizing the pulmonary surfactant administration with the breathing phase of the patient. To implement this feature, a pressure sensor 107 is inserted along the surfactant catheter, but externally to the pharyngeal tube, and provides an indirect but accurate measurement of the pharyngeal pressure swings. This measurement is possible because of the relatively low pressure in the channel conveying the surfactant, allowing the use of the surfactant line for measuring the retro-pharyngeal pressure with the aim of both synchronizing the atomization with the breathing pattern of the patients and to help the attending medical staff to place the catheter in the proper place and monitoring the maintenance of the proper position during the treatment, allowing the identification of wrong positioning of the catheter tip (e.g. into the oesophagus).
Figure 2 shows a specific implementation of the multi-channel catheter according to a preferred embodiment of the present invention. The air blasting atomizer of the present embodiment is realized by means of a multi-lumen catheter with a central inner lumen 201 surrounded by several smaller lumens 203. The surfactant flows into the main central lumen, driven by the infusion pump, while the gas (e.g. air, oxygen-enriched air or pure oxygen), flows through the lateral lumens. The pressure drop in the central catheter depends on its length and internal diameter. In a preferred embodiment of the present disclosure the catheter could present a length of 7-15 cm and an internal diameter of 0.4-0.6 mm. In this case the pressure drop is in the range of 7.8-0.72 cmH$_2$O, considering a flow of surfactant of 3 mL/20min. In this way a nozzle is not required and the particles size dimension is determined mainly by the pressure of the air which flows in the lateral channel. To generate the gas flow into the lateral lumens a compressor or a pressurized gas source (e.g. a cylinder or a medical gas wall plug) can be used: the pressure is modulated by a pressure regulator with a mechanical filter to avoid dust flowing through the system.

Such pressurized gas flow is not able to significantly alter the pressure in the pharynx, since the flow is rather limited and the anatomical structures are open to the atmosphere.

The distribution of the particles size obtained by means of the preferred embodiment of the present invention has been characterized by a commercial laser
diffractive size analyzer (Malvern, Insitec RT). The measurements have been carried out using exemplificative conditions of 0.5 bar of pressurized air and a surfactant flow rate of 3 mL/20 minutes.

As a result the most of the particles size is comprised between 100-200 microns. In particular the median value is 137.47 micron, the 10\textsuperscript{th} percentile is 39.50 micron, the 90\textsuperscript{th} percentile is 130.63 micron as reported in Figure 3.

As a possible additional feature the catheter used in the method and system of the present disclosure could be provided with some spacers on the external surface which help in positioning it and keeping a minimum distance between the catheter itself and the wall of the retro-pharyngeal cavity. This separation ensures that the atomised surfactant is conveyed to the lung by inspiratory airflow and not projected on the walls of the pharyngeal cavity. An example is shown in Figure 2b where some ribs are running along the external surface of the catheter; these ribs can also have a stiffening function adding some sort of rigidity to the catheter (as an alternative to the metal scaffolding mentioned above). Other shapes of the ribs are possible, e.g. they could be in the shape of one or more rings surrounding the catheter at predetermined distance one each other: those skilled in the art will appreciate that several equivalent alternatives can be implemented.

Laryngoscope is another tool known to the skilled person, that could be suitably utilized for positioning the catheter in the retro-pharyngeal cavity.
Moreover, Magill forceps, oro-pharyngeal cannulas such as cannula of Mayo, of Guedel, of Safar and of Bierman can facilitate the introduction of the catheter. In a preferred embodiment the cannula of Mayo is utilised for both facilitating the introduction and keeping the catheter tip in the proper position, i.e. not close to the pharyngeal wall and pointing toward the inlet of the trachea during the whole period of surfactant delivery.

Figure 4a shows a possible implementation of the pressure sensor 107 mentioned above, which is used in an embodiment of the present invention to detect the pressure of the air coming from or flowing into the pharyngeal cavity. Such measured pressure is used as an indication of the breathing rhythm of the patient and the system synchronizes the administration of the medicament accordingly. This synchronization brings big advantages both in term of efficacy of the treatment and in reducing the waste of medicament. The efficacy is due to the transportation of the atomized drug by the inspiratory flow; the saving is caused by the fact that the medicament is delivered only when needed, avoiding to waste it while the patient is exhaling. In an embodiment of the present disclosure the pressure sensor is inserted along the surfactant line and transduces the pressure from the tip of the catheter (i.e. the pressure in the neonate pharynx) to the sensing element which acts as a variable resistance. When the motor is activated the syringe gently pushes the surfactant into the atomizing catheter to allow an averaged flow of 3 ml/h (this parameter can be adjusted on the treatment program). As shown in Fig. 4b, the sensor exploits the piezoresistive phenomenon.
to convert the mechanical pressure into a voltage drop; it has an internal Wheatstone Bridge connection, which means that it is internally compensated for ambient temperature fluctuations.

The sensor can be for example a disposable pressure sensor, similar to those used for the invasive measurement of blood pressure.

The administration of surfactant only during the inspiration phase is a big advantage provided by the present invention: this results in a better control on the effective quantity which reaches alveoli and to avoid the waste of the supplied surfactant. This requires the measurement of a signal related to the breathing pattern in the ventilatory condition of the preterm neonate (spontaneously breathing and kept under nCPAP or other non-invasive ventilation procedure such as NIPPV) to detect the end-inspiration and end-expiration and to predict the 'future’ breathing pattern of the baby. According to an embodiment of the present invention, we start the administration of surfactant before the beginning of the inspiration and stop it before the beginning of the expiration in order to:

1) Take into account the mechanical delays in the atomization;
2) Prevent the loss of surfactant since the surfactant delivered at end inspiration will be still in the pharyngeal cavity and therefore exhaled during the beginning of the expiration.

In Figure 5 are reported retropharyngeal pressure tracings from a representative preterm baby with gestational age of 28 weeks and a body weight of 1650g. Panel a shows the whole track characterized by a very high variability with several
spikes and base line fluctuations; in panel b an enlargement of the same signal is reported. A statistical analysis on the data has been performed and a predictive algorithm has been designed. The main steps of which are reported in the flow chart of Figure 6, with the relative functions. In particular, after the removal of trends and high frequency noise, the signal is integrated to obtain a new signal proportional to the lung volume, and by looking for maxima and minima it is possible to detect the end-inspiratory and end-expiratory points. Our statistical analysis includes also the measurement of the pressure involved, which is about 1 cmH$_2$O in all the different conditions.

By using this approach we have obtained in an exemplificative simulation, the administration of the 97 ± 0.8% of surfactant in 60 ± 21 min in 7 preterm neonates with a gestational age of 29.5±3 weeks and a body weight of 1614g (± 424g).

All operations of the system here described are controlled by a microprocessor (e.g. microcontroller of PIC18F family by Microchip Technology Inc.) running a software adapted to implement the method according to a preferred embodiment of the present invention.

It will be appreciated that alterations and modifications may be made to the above without departing from the scope of the disclosure. Naturally, in order to satisfy local and specific requirements, a person skilled in the art may apply to the solution described above many modifications and alterations. Particularly, although the present disclosure has been described with a deep degree of
particularity with reference to preferred embodiment(s) thereof, it should be understood that eventual omissions, substitutions and changes in the form and details as well as other embodiments are possible; moreover, it is expressly intended that specific elements and/or method steps described in connection with any disclosed embodiment of the disclosure may be incorporated in any other embodiment as a general matter of design choice.

For example, similar considerations apply if the components (e.g. microprocessor or computers) have different structure or include equivalent units; in any case, it is possible to replace the computers with any code execution entity (such as a PDA, a mobile phone, and the like).

Similar considerations apply if the program (which may be used to implement some embodiments of the disclosure) is structured in a different way, or if additional modules or functions are provided; likewise, the memory structures may be of other types, or may be replaced with equivalent entities (not necessarily consisting of physical storage media). Moreover, the proposed solution lends itself to be implemented with an equivalent method (having similar or additional steps, even in a different order). In any case, the program may take any form suitable to be used by or in connection with any data processing system, such as external or resident software, firmware, or microcode (either in object code or in source code).

Moreover, the program may be provided on any computer-usable medium; the medium can be any element suitable to contain, store, communicate, propagate, or transfer the program. Examples of such medium are fixed disks (where the
program can be pre-loaded), removable disks, tapes, cards, wires, fibres, wireless connections, networks, broadcast waves, and the like; for example, the medium may be of the electronic, magnetic, optical, electromagnetic, infrared, or semiconductor type.

In any case, the solution according to the present disclosure lends itself to be carried out with a hardware structure (for example, integrated in a chip of semiconductor material), or with a combination of software and hardware. The system of the invention is particularly suitable for the prevention and/or treatment of the respiratory distress syndrome (RDS) of the neonate (nRDS). However, it could be advantageously utilised for the prevention and/or treatment of the adult/acute RDS (ARDS) related to a surfactant-deficiency or dysfunction as well as of conditions in which respiratory distress may be present as a consequence of, for instance, meconium aspiration syndrome, pulmonary infection (e.g. pneumonia), direct lung injury and bronchopulmonary dysplasia.

Advantageously, the system of the invention is applied to pre-term neonates who are spontaneously breathing, and preferably to extremely low birth weight (ELBW), very-low-birth-weight (VLBW), and low-birth weight (LBW) neonates of 24-35 weeks gestational age, showing early signs of respiratory distress syndrome as indicated either by clinical signs and/or supplemental oxygen demand (fraction of inspired oxygen ($FiO_2$) > 30%).

More advantageously, nasal Continuous Positive Airway Pressure (nCPAP) is applied to said neonates, according to procedures known to the person
skilled in the art. Preferably a nasal mask or nasal prongs are utilised. Any nasal mask commercially available may be used, for example those provided by The CPAP Store LLC, and the CPAP Company. Nasal CPAP is typically applied at a pressure comprised between 1 and 12 cm water, preferably 2 and 8 cm water, although the pressure can vary depending on the neonate age and the pulmonary condition. Other non-invasive ventilation procedures such as nasal intermittent positive-pressure ventilation (NIPPV), High Flow Nasal Cannula (HFNC), and bi-level positive airway pressure (BiPAP) can alternatively be applied to the neonates. The invention is illustrated in detail by the following Example. In vivo efficacy of atomized surfactant (in this example poractant alfa, as defined above) was evaluated in preterm newborn rabbits at the 27th day of gestation (term = 31±1 days). The model chosen closely resembles the conditions of premature babies affected by RDS in that the lungs of these animals are not yet able to produce their own surfactant, but can warrant gas exchange so that they can expand in response to exogenous surfactant administration. Treatments were intratracheally given at 2 ml/kg volume, corresponding to 160 mg/kg dose. Foetuses, paralyzed with pancuronium bromide (0.02 mg i.p.), were then placed in the plethysmograph system at 37°C and ventilated with pure oxygen at constant pressure (frequency 40/min, inspirationexpiration ratio 60/40). No positive end-expiratory pressure (PEEP) was applied. An "opening" pressure of 35 cmH₂O was first applied for 1 min to overcome initial resistance due to capillarity
in finer conducting airways. It was then followed by 15 min at 25 cmH$_2$O, 5 min at 20 cmH$_2$O, 5 min at 15 cmH$_2$O and again at 25 cmH$_2$O for the final 5 min.

Respiratory flow was measured every 5 min by a Fleish tube connected to each chamber of the plethysmograph system. Tidal volume (Vt) was automatically obtained by integration of the flow curve.

Two sets of experiments were performed.

In the first set, five samples (1 ml each) have been received. The pulmonary surfactant administered at each samples is respectively: not atomized poractant alfa, poractant alfa atomized at an air pressure of 0.0, 0.2, 0.5 and 0.8 bar. The pulmonary surfactant has been atomized using the preferred embodiment of the present invention.

In this set of experiments a control group without any treatment was included.

All the atomized samples, including that passed through without any pressure applied, resulted as effective as not atomized poractant alfa (P<0.05, one-way ANOVA followed by Tukey's test; Graphpad Prism). No statistically significant difference was found between the different conditions of atomization.

In the second set, three samples (1 ml each) have been received. The pulmonary surfactant administered at each samples is respectively: non-atomized poractant alfa, poractant alfa atomized at an air pressure of 0.2, 0.5 and 0.8 bar.

In this set of experiments two further groups were included, a control group without any treatment and a group treated with a batch of poractant alfa already released to the market.
The same results were observed in the second set of experiments.

As the results were consistent in the two sets, the data have been pooled (Figure 7). Statistical analysis of these data confirmed the previous results.

In conclusion the passage through the atomizer, using the preferred embodiment of this invention, does not affect poractant alfa efficacy in premature rabbit foetuses. In particular atomization at pressures between 0.2 and 0.8 bar does not significantly affect poractant alfa efficacy and the application of 0.5 bar seems the most suitable although no statistically significant difference has been observed between different atomization conditions.
Claims

1. A system for delivering a medicament to spontaneously breathing patients, comprising:
   - i) a flexible catheter adapted to reach the retro-pharyngeal region of the patient, the catheter including at least a first channel being adapted to convey in the patient's pharyngeal region a flow of liquid medicament and at least a second channel adapted to convey in the patient's pharyngeal region a pressurized flow of gas,
   - ii) first pump means connected to a first end of the at least first channel, adapted to create a pressure which pushes the column of liquid medicament towards the second end of the at least first channel;
   - iii) second pump means connected to a first end of the at least second channel, adapted to create the flow of pressurized gas; so that when the column of liquid medicament and the pressurized gas meet in the pharyngeal cavity, the liquid column is broken into a plurality of particles causing the atomized medicament to be delivered into the patient's lungs;
   - iv) a pressure sensor connected to the at least first channel for measuring a value indicative of the pressure in the patient pharyngeal cavity, such value being use to determine whether the patient is in an inspiration or in an expiration phase and wherein the first pump means are selectively activated only during inspiration phase.
2. The system according to claim 1, wherein the at least second channel includes a plurality of channel arranged around the first channel.

3. The system according to claim 1 or 2, wherein the catheter is made of flexible plastic material.

4. The system according to claim 3, wherein the catheter includes a partially rigid scaffolding.

5. The system according to any one of the preceding claims wherein the catheter includes spacers means arranged on its external surface so that, when the catheter is in place for the aerosol treatment, the second end of the at least first and at least second channel are kept separated from the wall of the pharyngeal cavity.

6. The system according to any one of the preceding claims, wherein the aerosol medicament includes a pulmonary surfactant.

7. The system according to claim 6, wherein the pulmonary surfactant is selected from the group consisting of modified natural pulmonary surfactants, artificial surfactants, and reconstituted surfactants.
8. The system according to claim 7, wherein the modified natural pulmonary surfactant is poractant alfa.

9. The system according to claim 7, wherein the pulmonary surfactant is a reconstituted surfactant.

10. The system according to any one of the preceding claims, wherein the pressurized gas includes air.

11. The system according to any preceding claim, wherein the patient is a spontaneously breathing pre-term neonate.

12. A computer implemented method for delivering an atomized medicament to a spontaneously breathing patient including:
   - selectively activating first pump means for providing in the retropharyngeal cavity by means of a multi-channel flexible catheter a low pressure column of liquid medicament through at least a first channel of the multi-channel catheter;
   - selectively activating second pump means for providing a pressurized flow of gas through at least a second channel of the multi-channel catheter;
   - detecting, by means of a pressure sensor being connected to the at least first channel, the inspiration activity of the patient;
wherein the liquid column of medicament is broken into a plurality of particles when the liquid column and the pressurized flow of gas meet in the retropharyngeal cavity, so that the atomized medicament is delivered into the patient's lungs; and wherein the step of providing liquid medicament through at least a first channel of the multi-channel catheter is performed only during the inspiration activity.

13. A computer program for implementing the steps of the method of claim 12, when the program is executed on a computer.

14. A method for preventing and/or treating a respiratory distress syndrome in spontaneously breathing patient, said method comprising the step of delivering an atomized medicament to the retro-pharyngeal region of the patient by means of a multi-channel flexible catheter a low pressure column of liquid medicament through at least a first channel of the multi-channel catheter and an pressurized flow of gas through at least a second channel of the multi-channel catheter; wherein the liquid column of medicament is broken into a plurality of particles when the liquid column and the pressurized flow of gas meet in the pharyngeal cavity

15. The method according to claim 14 further comprising the step of detecting by means of a pressure sensor, being connected to the at least first channel, the
inspiration activity of the patient; wherein said step of providing is performed only during the inspiration activity.

16. The method according to claim 14 or 15, wherein the medicament is a pulmonary surfactant.

17. The method of claim 16 wherein the pulmonary surfactant is poractant alfa.

18. The method according to claim 16 wherein the pulmonary surfactant is a reconstituted surfactant.

19. The method according to claim 14 comprising the step of applying to the patient a non-invasive ventilation procedure.

20. The method according to claim 19 wherein nasal Continuous Positive Airway Pressure (nCPAP) with a nasal device such as a mask or prongs is applied to the patient.

21. The method according to claim 14, wherein the patient is a spontaneously breathing pre-term neonate.
22. A kit comprising: a) a pharmaceutical composition comprising a pulmonary surfactant suspended in a pharmaceutically acceptable aqueous medium; b) the system of the invention; c) means for positioning and/or facilitating the introduction of the catheter into the retro-pharyngeal region; and d) container means for containing the pharmaceutical composition, the system and the positioning means.
## A. Classification Of Subject Matter

INV. A61M11/06 A61M11/02 A61M15/00 A61M25/00 A61M31/00
ADD. A61M16/04 A61M15/08 A61M16/00 A61B5/03 A61B5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. Fields Searched

Minimum documentation searched (classification system followed by classification symbols)

A61M A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

## C. Documents Considered To Be Relevant

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP 0 692 273 Al (TRUDELL MEDICAL LTD [CA]) 17 January 1996 (1996-01-17) cited in the application on the whole document</td>
<td>1-11, 13, 22</td>
</tr>
<tr>
<td>A</td>
<td>WO 01/23025 Al (INSTRUMENTARIUM CORP [FI]) 5 April 2001 (2001-04-05) the whole document</td>
<td>1-11, 13, 22</td>
</tr>
<tr>
<td>A</td>
<td>US 2009/199848 Al (SHARRATT TODD W [US]) 13 August 2009 (2009-08-13) the whole document</td>
<td>1-11, 13, 22</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

- **A** document defining the general state of the art which is not considered to be of particular relevance
- **E** earlier application or patent but published on or after the international filing date
- **L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- **O** document referring to an oral disclosure, use, exhibition or other means
- **P** document published prior to the international filing date but later than the priority date claimed

**T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**X** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**Y** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**A** document member of the same patent family

Date of the actual completion of the international search: 14 May 2013

Date of mailing of the international search report: 24/05/2013

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer: Azaïzia, Mourad
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
<tr>
<td>A</td>
<td>DE 10 2010 025045 A1 (JOCHUM FRANK [DE]) 22 December 2011 (2011-12-22)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
<tr>
<td>A</td>
<td>US 4 535 766 A (BAUM MARCEL [AT]) 20 August 1985 (1985-08-20)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
<tr>
<td></td>
<td>the whole document</td>
<td>1-11, 13,</td>
</tr>
</tbody>
</table>
### INTERNATIONAL SEARCH REPORT

#### Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 12, 14-21
   - because they relate to subject matter not required to be searched by this Authority, namely:
     - Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
   - Remarks [ ]

2. **□** Claims Nos.: 12, 14-21
   - because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
   - Remarks [ ]

3. **□** Claims Nos.: 12, 14-21
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
   - Remarks [ ]

#### Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. **□** As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. **□** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of additional fees.

3. **□** As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 12, 14-21

4. **□** No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 12, 14-21

**Remark on Protest**

- **□** The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- **□** The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- **□** No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AT 527009 T</td>
<td>15-10-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 700225 B2</td>
<td>24-12-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2169995 A</td>
<td>04-01-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 9502836 A</td>
<td>06-02-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2152002 A1</td>
<td>18-12-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69532843 D</td>
<td>13-05-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69532843 T2</td>
<td>28-04-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1433493 A2</td>
<td>30-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3746090 B2</td>
<td>15-02-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004081890 A</td>
<td>18-03-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2006289116 A</td>
<td>26-10-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 272354 A</td>
<td>24-10-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2141351 Cl</td>
<td>20-11-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5964223 A</td>
<td>12-10-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6526976 B1</td>
<td>04-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009107503 A</td>
<td>30-04-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 9504936 A</td>
<td>27-02-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 0123025 AI</td>
<td>05-04-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 9530448 AI</td>
<td>16-11-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009199848 AI</td>
<td>13-08-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1426057 AI</td>
<td>09-06-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 4528518 B2</td>
<td>18-08-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004184419 A</td>
<td>02-07-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004192604 A</td>
<td>30-09-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008000470 AI</td>
<td>03-01-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005229926 AI</td>
<td>20-10-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 102010025045 AI</td>
<td>22-12-2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 4535766 A</td>
<td>20-08-1985</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BE 895945 A</td>
<td>16-06-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CH 657781 A5</td>
<td>30-09-1986</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 3206482 A</td>
<td>03-11-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FR 2522168 A</td>
<td>26-08-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GB 2114896 A</td>
<td>01-09-1983</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP S58155870 A</td>
<td>16-09-1983</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (April 2005)
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NL 8204263 A</td>
<td>16-09-1983</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SE 456219 B</td>
<td>19-09-1988</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SE 8206830 A</td>
<td>24-08-1983</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 4535766 A</td>
<td>20-08-1985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>US 4813431 A</td>
<td>21-03-1989</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>